Cover Image
市場調查報告書

Eluxadoline (大腸躁鬱症) - 2023年為止的預測與市場分析

Eluxadoline (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 325978
出版日期 內容資訊 英文 58 Pages
訂單完成後即時交付
價格
Back to Top
Eluxadoline (大腸躁鬱症) - 2023年為止的預測與市場分析 Eluxadoline (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023
出版日期: 2014年12月31日 內容資訊: 英文 58 Pages
簡介

本報告提供大腸躁鬱症 (IBS) 治療藥物──Eluxadoline之相關調查,提供您疾病概要與免疫學,疾病管理,競爭情形,未滿足需求機會,開發平台評估,主要企業的資訊,今後的市場預測等資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因與病理學
    • 病因
    • 病理學
  • 分類
  • 症狀
  • 預後
  • 生活品質 (QOL)

第4章 疾病的管理

  • 疾病和治療概要
    • 診斷
    • 治療指南主要的處方藥
    • 臨床診療

第5章 競爭評估

  • 概要

第6章 未滿足需求和機會

  • 概要
  • 更有效的藥物療法
    • 未滿足需求
    • 差距分析
    • 機會
  • IBS D類型的治療方法
    • 未滿足需求
    • 差距分析
    • 機會
  • IBS M類型的治療方法
    • 未滿足需求
    • 差距分析
    • 機會
  • 解決腹痛和飽脹感症狀的治療方法
    • 未滿足需求
    • 差距分析
    • 機會
  • 提高IBS的診斷率
    • 未滿足需求
    • 差距分析
    • 機會

第7章 開發平台評估

  • 概要
  • 臨床開發的潛力治療藥物

第8章 Eluxadoline

  • 概要
  • 有效性
  • 安全性
  • 給藥與處方
  • 潛在的臨床性·商業性地位
  • SWOT分析
  • 預測

第9章 附錄

目錄
Product Code: GDHC521DFR

Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients' quality of life (QOL). In terms of volume, the IBS market is a large, albeit naive, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.

Eluxadoline is being developed for the treatment of IBS-D. As of October 2014, it had reached the Phase III stage of development, and also has been granted a Fast-Track designation by the FDA. Furiex Pharmaceuticals initially licensed eluxadoline from Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson [J&J]) for the development of the product. Subsequently, Furiex was fully-acquired by Actavis in July 2014 (Furiex Pharmaceuticals, press release, July 2, 2014).

Scope

  • Overview of IBS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Eluxadoline including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Eluxadoline for the top 7 countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, UK and Japan.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return.
  • Stay ahead of the competition by understanding the changing competitive landscape for IBS.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
  • Make more informed business decisions from insightful and in-depth analysis of Eluxadoline performance.
  • Obtain sales forecast for Eluxadoline from 2013-2023 in top 7 countries (the US, France, Germany, Italy, Spain, UK and Japan).

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Classification
  • 3.3. Symptoms
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. More Effective Pharmacotherapies
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Therapies for the IBS-D Subtype
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Therapies for the IBS-M Subtype
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Therapies to Address Abdominal Pain and Bloating Symptoms
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Improved Diagnosis Rate for IBS
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development

8. Eluxadoline

  • 8.1. Overview
  • 8.2. Efficacy
  • 8.3. Safety
  • 8.4. Dosing and Formulation
  • 8.5. Potential Clinical and Commercial Positioning

8.6. SWOT Analysis

  • 8.7. Forecast

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed IBS Patients
    • 9.4.2. General Pricing Assumptions
    • 9.4.3. Generic Erosion
    • 9.4.4. Pricing of Pipeline Agents
  • 9.5. Primary Research - KOLs Interviewed for This Report
  • 9.6. Primary Research - Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Analyst
    • 9.7.2. Therapy Area Director
    • 9.7.3. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Common Symptoms of IBS
  • Table 2: Summary of the Various Diagnostic Criteria Used for the Diagnosis of IBS
  • Table 3: Treatment Guidelines for IBS
  • Table 4: Leading Prescribed Drugs for IBS by Predominant Symptoms in the 7MM, 2014†
  • Table 5: Leading Branded Treatments for IBS, 2014
  • Table 6: Unmet Needs and Opportunities in IBS
  • Table 7: Drugs in Late-Stage Clinical Development for IBS, 2014
  • Table 8: Product Profile - Eluxadoline
  • Table 9: Eluxadoline SWOT Analysis, 2014
  • Table 10: Global IBS Sales Forecasts ($m) for Eluxadoline, 2013-2023
  • Table 11: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: Summary of Pharmacotherapies Used to Treat IBS
  • Figure 2: IBS - Phase IIb-III Pipeline, October 2014
  • Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in IBS, 2013-2023
  • Figure 4: Clinical and Commercial Positioning of Eluxadoline
Back to Top